Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes

Evaluation of Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart or Insulin NPH in Subjects With Type 2 Diabetes

This trial is conducted in South America. The aim of this trial is to evaluate the efficacy of metformin plus biphasic insulin aspart or insulin NPH on blood glucose control in subjects with type 2 diabetes.

Inclusion Criteria:

• Type 2 diabetes
• Currently treated with insulin NPH or are insulin-naive
• Body mass index (BMI) below 35.0 kg/m2
• HbA1c between 7.5-11.0%

Exclusion Criteria:

• Participation in any other clinical trial involving investigational products within the last 3 months
• History of drug or alcohol dependence
• Known impaired hepatic function
• Known or suspected allergy to human insulin NPH, insulin aspart or any component of the composition